Hypertension

This page includes news and new technology on hypertension. The condition is caused by abnormally high blood pressure that causes excess force and pressure of the blood against the artery walls. Long-term, this can cause damage the vessels and contributes to heart disease. Therapies include antihypertensive medications such as diurestics and renal denervation therapy.

CinCor Pharma, Inc. announced the publication of Phase 1 clinical data for baxdrostat, a highly selective, once daily, oral small molecule inhibitor of aldosterone synthase, in the journal Hypertension Research.

News | Hypertension

CinCor Pharma Announces Publication of Phase 1 Multiple Ascending Dose Study Data in Hypertension Research

October 24, 2022 — CinCor Pharma, Inc. announced the publication of Phase 1 clinical data for baxdrostat, a highly ...

October 24, 2022

The data, collected during the transition from intravenous (IV) to oral levosimendan in the open-label extension (OLE) of the HELP (Hemodynamic Evaluation of Levosimendan in PH-HFpEF) trial, were presented at the Heart Failure Society of America (HFSA) Scientific Sessions 2022

News | Heart Failure

Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

October 13, 2022 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing, and ...

October 13, 2022

CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 2 data from its BrigHtn trial evaluating baxdrostat in patients with treatment-resistant hypertension as part of the late-breaking science session

News | Hypertension

CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data for Baxdrostat in Treatment-Resistant Hypertension at the Upcoming 2022 American Heart Association Scientific Sessions

October 5, 2022 — CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 2 data from ...

October 05, 2022

Study of the Paradise Ultrasound Renal Denervation System Shows Significant Reduction in Blood Pressure in Patients with Uncontrolled Hypertension

News | Hypertension

ReCor Medical Announces Results of RADIANCE II Pivotal Trial at TCT 2022 Annual Meeting

September 26, 2022 — ReCor Medical, Inc., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced the ...

September 26, 2022

Statistically significant mean reductions of 10.3 mmHg in 24-hour ambulatory systolic blood pressure and 11.7 mmHg in ambulatory pulse pressure after 6 months of therapy in control patients who crossed over to BackBeat CNT following completion of the randomized portion of the MODERATO II study

News | Hypertension

Orchestra BioMed Announces Presentation of Positive Long-Term Clinical Results from MODERATO II Control Patients Crossover Extension Study of BackBeat CNT at TCT 2022

September 20, 2022 — Orchestra BioMed, Inc., a biomedical innovation company accelerating high-impact technologies to ...

September 20, 2022

Computed tomography 3D surface rendering of the lungs and heart from a patient with pulmonary arterial hypertension demonstrating trachea and major airways (yellow), an enlarged heart (red), enlarged main pulmonary artery (large blue vessel on top of heart) and thinning of the peripheral pulmonary vessels (blue). Marcus Y. Chen, M.D., NHLBI

News | Hypertension

Novel Blood Test Helps Evaluate Severity in Pulmonary Arterial Hypertension, a Rare Lung Disease

September 12, 2022 — Researchers at the National Institutes of Health have found that a novel blood test can be used to ...

September 12, 2022

The illustration shows a portion of the receptor pGC-A, known as the extracellular domain, which protrudes from cell surfaces in the cardiovascular system. Small molecules bind with the receptor and exert subtle control over blood pressure. The new research offers the first sneak peek at the full-length receptor, a vital step in the development of new drugs to treat hypertension and other afflictions.

News | Hypertension

New Study Explores Cell Receptor Crucial for Cardiovascular Health

August 8, 2022 — Cardiovascular diseases remain a leading cause of death around the world. A primary contributor to ...

August 08, 2022

RADIANCE II US FDA IDE pivotal trial evaluating the Paradise Ultrasound Renal Denervation (uRDN) System as a treatment for hypertension met its primary efficacy endpoint, demonstrating a statistically significant reduction in daytime ambulatory systolic blood pressure between treatment and a sham procedure measured at two months

News | Hypertension

ReCor Medical and Otsuka Medical Devices Announce Primary Endpoint Met in the RADIANCE II US Pivotal Trial of the Paradise System for the Treatment of Hypertension

July 29, 2022 — ReCor Medical, Inc. and Otsuka Medical Devices Co., Ltd., a fully owned subsidiary of Otsuka Holdings ...

July 29, 2022

Back on track after its in-person hiatus, ACC22 stressed industry resilience, and featured practice-changing science and innovations

Feature | ACC | By Melinda Taschetta-Millane

ACC22: Transforming Cardiovascular Care

In April, the cardiology community converged face-to-face in Orlando for The American College of Cardiology’s (ACC22) ...

May 11, 2022

Pfizer is voluntarily recalling five (5) lots of Accupril (Quinapril HCl) tablets distributed by Pfizer to the patient (consumer/user) level due to the presence of a nitrosamine, Nnitroso-quinapril, observed in recent testing above the Acceptable Daily Intake (ADI) level.

News | Heart Failure

Pfizer Issues Voluntary Nationwide Recall of ACCUPRIL (Quinapril HCl)

April 25, 2022 — Pfizer is voluntarily recalling five (5) lots of Accupril (Quinapril HCl) tablets distributed by Pfizer ...

April 25, 2022

Among patients undergoing non-cardiac surgery who were also on blood pressure medications, a multifaceted strategy to try to keep their blood pressure from dropping to a potentially dangerous low level immediately before, during and for up to two days after surgery made no difference in the rates of major cardiovascular events in the 30 days following surgery.

News | Hypertension

Blood Pressure Management Strategy During Surgery Has No Impact on Major Cardiovascular Complications

April 7, 2022 – Among patients undergoing non-cardiac surgery who were also on blood pressure medications, a ...

April 07, 2022

News | ACC

Esperion Announces Two NEXLETOL Data Presentations at ACC.22

April 4, 2022 – Esperion presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL) ...

April 04, 2022

MedWatch, The FDA Safety Information and Adverse Event Reporting Program, announced today that Pfizer is recalling Accuretic (quinapril hydrochloride/hydrochlorothiazide) tablets distributed by Pfizer as well as two authorized generics distributed by Greenstone (quinapril HCL and hydrochlorothiazide and quinapril HCl/hydrochlorothiazide) due to the presence of a nitrosamine, N-nitroso-quinapril, above the Acceptable Daily Intake level.

News | Hypertension

FDA Recalls Quinapril Hydrochloride and Hydrochlorothiazide Tablets by Pfizer

March 23, 2022 — MedWatch, The FDA Safety Information and Adverse Event Reporting Program, announced today that Pfizer i ...

March 23, 2022

News | Hypertension

Two Elevated Biomarkers Distinguish Blacks with Resistant Hypertension

February 25, 2022 – University of Alabama at Birmingham researchers are calling for a wider study of racial differences ...

February 25, 2022

VitalSight was designed to help the 37 million Americans who have uncontrolled Stage 2 hypertension and live every day with a higher risk of heart attack and stroke

News | Remote Monitoring

VitalSight in the U.S., Hypertension Plus in the U.K., Recognized as Outstanding Health Technology at CES 2022

February 8, 2022 — OMRON Healthcare, Inc., the global leader in remote blood pressure monitoring and personal health ...

February 08, 2022